A staffer at Newton Wellesley Hospital helps conduct a bone density scan on a patient.
(Bill Polo/Globe Staff/File 2007)
MARKET MOVERS
Bone-drug tests lift Amgen’s shares
A staffer at Newton Wellesley Hospital helps conduct a bone density scan on a patient.
(Bill Polo/Globe Staff/File 2007)
July 9, 2009
- |
Amgen Inc. of Thousand Oaks, Calif., had the best gain in the Standard & Poor’s 500. The world’s largest biotechnology company (with facilities in Cambridge and West Greenwich, R.I.) said its lead experimental product, a bone-strengthening drug called denosumab, did a better job in a clinical trial than Novartis AG’s Zometa to delay fractures in breast cancer patients whose illness had spread to the bones.
© Copyright 2009 Globe Newspaper Company.
